Skip to content

SANOPHAR

Active Public limited companyfounded 2000active for 26 yearsVolkslaan 111, 8930 MenenKBO/BCE: BE 0471.640.823

Lifetime

20 annual accounts with figures on one time axis, 25 filings since 2001
peak of €752,333 in 2020
€352,673▼ 13.1%
lowest -€45,096 in 2008
€98,632▼ 43.2%
peak of €477,087 in 2025
€477,087▲ 0.1%
€690,270▼ 2.5%
peak of 7.9 FTE in 2021
2.9 FTE▲ 7.4%
Board2 names since 2014
2 directors and 1 other
Owners2 names in the annual accounts
50%
Documentsfilings and deeds
01-07-202630 days before the deadline
2025abbreviated format
Gross margin from €406,062 to €352,673Result from €173,715 to €98,632

Key points

from the 2025 annual accounts

Equity

€477,087 ▲ 0.1%

SANOPHAR has made a profit without a break since 2009.

Result

€98,632 ▼ 43.2%
€174,0002024€98,6002025

The result fell in 2025 from €173,715 to €98,632.

Staff

2.9 FTE from 7.9 in 2021

Between 2021 and 2025, the number of full-time equivalents fell by 63%.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,390 companies had the same profile as SANOPHAR has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,390 companies, not a prediction for SANOPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 09-06-2020
Director,
  • 50%score equity €240,699 (2025) · annual accounts 2025 of
  • 50%score equity €2.0m (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0471640823
Registered office moved from Wevelgem to Menen The registered office moved from Menenstraat 295, 8560 Wevelgem to Volkslaan 111, 8930 Menen · acts as permanent representative · Board meeting of 04-09-2023 · Gazette deed
2 directors appointed, 1 resignation resigns · , and act as permanent representatives · and appointed · General meeting of 31-12-2022 · Gazette deed
Demerger: SANOPHAR splits off to FARMAVE Capital increase of €350,000 · 1,089 new shares · Contributions by (€5,555.55); (€344,444.45) · General meeting of 05-07-2021 · Gazette deed
All 41 events

Comparable companies

same main activity, similar in size and age
Company
SANOPHAR Menen €1.2m €352,673 40.9% 2.9
APOTHEEK VERSTEELE Veurne €1.2m €349,476 69.6% 3.3
PHARMACIE LEDOUX - POZZI Anhée €1.1m €333,395 34.0% 2.9
APOTHEEK LAURYSSEN Antwerp €1.2m €335,487 7.8% 3.1
DELTAPHAR Auderghem €1.1m €310,408 -0.5% 2.8
Apotheek Wijchmaal Peer €1.2m €332,635 29.9% 2.7
APOTHEEK DENYS ZANDHOVEN Zandhoven €1.2m €397,159 76.9% 2.6

These companies have the same main activity as SANOPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.1m and €1.2m, founded between 1997 and 2003.

Official details

Source: KBO
Status
Active since 14-04-2000Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment units
2.186.047.3298930 Menen, since 05-06-2008
2.186.047.5278930 Menen, registered on 05-06-2008
Financial year end
31 December
Peppol
Reachable since 04-06-2025
Company details

Annual accounts 2025

≈ €1.2mestimated
€1.2m▼ 1.4%
Employeeson 31-12-2025
5=
Filing
Filed on 01-07-2026, 30 days before the end of the filing period
Financials

Insights on SANOPHAR

SANOPHAR files the abbreviated format. That format states no turnover. The gross margin rose from €104,245 in 2006 to €352,673 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about SANOPHAR

What is the company number of SANOPHAR?
The company number of SANOPHAR is 0471.640.823. The VAT number is the same number with BE in front: BE 0471.640.823.
Where is SANOPHAR based?
The registered office is at Volkslaan 111, 8930 Menen.Company details
What does SANOPHAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of SANOPHAR?
SANOPHAR is a public limited company (NV).
When was SANOPHAR founded?
SANOPHAR was founded on 14-04-2000.
Is SANOPHAR still active?
Yes, SANOPHAR is an active enterprise in the KBO register.
How many employees does SANOPHAR have?
SANOPHAR had an average of 2.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does SANOPHAR fall under?
In its 2025 annual accounts, SANOPHAR states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of SANOPHAR?
The turnover in financial year 2025 is about €1.2m. This figure is estimated from the gross margin of €352,673 and 42 comparable companies (NACE 477). It probably lies between €960,000 and €1.7m.
Is SANOPHAR profitable?
In financial year 2025, SANOPHAR made a profit of €98,632.
Where can I find the annual accounts of SANOPHAR?
SANOPHAR filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of SANOPHAR due?
SANOPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.